STEAP4 and cancer: Through comprehensive single‐cell transcriptomic profiling of ENZ‐naïve and ENZ‐treated tumors, an expansion of ENZ‐resistant myofibroblastic cancer‐associated fibroblast (designated STEAP4+ myoCAF) is identified that correlates with adverse clinical outcomes.